Pulling SEC filings + quote and writing the call…

TriSalus Life Sciences, Inc.
Next earnings Aug 10, 2026 · consensus $-0.16 EPS, $10.5M rev
Last earnings +0.4% on 2026-05-12
Revenue grew 53.4% YoY; but unprofitable (net margin -86.9%).
TriSalus Life Sciences, Inc. shows $45.2M in FY2025 revenue (+53.4% YoY), a -86.9% net margin.
Sources: SEC EDGAR (CIK 0001826667, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 11:25:11 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $12.4M | $18.5M | $29.4M | $45.2M |
| Gross profit | — | $10.1M | $15.9M | $25.3M | $38.2M |
| Operating income | -$3.04M | -$36.4M | -$54.5M | -$36.2M | -$26.9M |
| Net income | $4.77M | -$47.2M | -$59.4M | -$30.0M | -$39.2M |
| Diluted EPS | — | -$161.55 | -$6.77 | -$1.31 | -$1.84 |
| Net margin | — | -380.6% | -320.7% | -102.1% | -86.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 6 open-market buys · 1 sale
| 2026-05-15 | Marshak Richard Chief Commercial Officer | Sell | 543.00 @ $2.67 | $1.45K |
| 2026-05-15 | Wahlstrom Mats Director | Buy | 60.0K @ $2.53 | $152K |
| 2026-05-15 | Stansky Michael P Director | Buy | 410K @ $2.50 | $1.02M |
| 2026-05-15 | Stansky Michael P Director | Buy | 200K @ $2.50 | $500K |
| 2026-05-15 | Szela Mary T CEO and President | Buy | 39.7K @ $2.59 | $103K |
| 2026-05-15 | Patience David Chief Financial Officer | Buy | 7.10K @ $2.43 | $17.3K |
| 2026-05-15 | Gordon Gary B. Director | Buy | 10.0K @ $2.46 | $24.6K |
| 2026-05-14 | HICKS KERRY R Director | Award | 28.2K | |
| 2026-05-14 | Wahlstrom Mats Director | Award | 37.6K | |
| 2026-05-14 | Wahlstrom Mats Director | Award | 34.2K |